MedCity News
NOVEMBER 5, 2023
Available atopic dermatitis drugs work by blocking inflammation, but Triveni Bio is developing an antibody that addresses a root cause of the chronic condition. The startup is out of stealth to advance its lead program and a pipeline of other inflammation and immunology drugs.
pharmaphorum
NOVEMBER 5, 2023
Innoviva’s ‘game changer’ antibiotic tackles gonorrhoea Phil.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
NOVEMBER 5, 2023
CMS finalized updates to its physician fee schedule for 2024, as well as finalized the rule for next year’s Outpatient Prospective Payment System (OPPS). Provider groups are displeased with the updated rules, arguing that both physicians and provider organizations need more monetary relief than what the agency is offering.
Cesare Ferrari
NOVEMBER 5, 2023
In my previous post, I discussed key accounts and their role in product development. Today I would take the analysis several steps further by sharing a few common mistakes in selecting and categorizing key accounts. In my experience in medical device marketing, suppliers and distributors are frequently small and medium size companies and I have always believed their process to properly identify and select their key accounts can be improved.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
NOVEMBER 5, 2023
Medicare needs to incentivize providers by reimbursing them for identifying and addressing social determinants of health. Doing so will ultimately improve patient health outcomes and simultaneously save risk-bearing organizations money.
Contrarian Sales Techniques
NOVEMBER 5, 2023
In the ever-evolving landscape of global commerce, the art of selling has become a nuanced ballet of persuasion, analytics, and strategy. The difference between stagnant sales and exponential growth can often be traced back to a company’s willingness to adapt and innovate in its sales strategy. As we pull back the curtain on the sales strategies of industry titans, we find actionable insights ripe for the picking.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PharmaTech
NOVEMBER 5, 2023
When a large CDMO couldn’t give a mid-size pharma company the proper attention, Adare stepped in to help manufacture CTM batches and get their project to the clinic quickly.
MedCity News
NOVEMBER 5, 2023
The “right” investment banker for you with the appropriate experience can not only tell you what your company is worth, they can also utilize their expertise to establish and run an appropriate, bespoke transaction process that will serve to reduce risk and maximally benefit you and your company’s future potential, valuation or even sale price – and they should be equally willing and able to
Pharmacy Times
NOVEMBER 5, 2023
Other than dialysis, Shah notes that patients with kidney disease who are pregnant can receive either nifedipine or labetalol to control blood pressure.
Pharmaceutical Technology
NOVEMBER 5, 2023
Two more medtech darlings have closed their doors this week, signalling an end to the funding rush of Covid.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacy Times
NOVEMBER 5, 2023
Nickolas also describes how the use of novel imaging technologies, microRNA, and transcriptomics help experts better understand underlying pathogenesis of ROD.
Pharmaceutical Technology
NOVEMBER 5, 2023
ABP-671 is under clinical development by Jiangsu Atom Bioscience and Pharmaceutical and currently in Phase II for Hyperuricemia.
Pharmacy Times
NOVEMBER 5, 2023
Deep-rooted discrimination and stigma can contribute to stressors that worsen disease progression and access to care, according to experts.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Myeloproliferative Disorders.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
PharmaTech
NOVEMBER 5, 2023
In this article, gain insights into how early-stage pharmaceutical product development is foundational for successful clinical trials and regulatory approvals, and why collaboration with experienced partners like CDMOs is essential.
Pharmaceutical Technology
NOVEMBER 5, 2023
XB-002 is under clinical development by Exelixis and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).
PharmaTech
NOVEMBER 5, 2023
A discussion of the FDA's guidance on nitrosamine impurities, various approaches for reducing the presence of impurities, and how Adare's unique nitrosamine mitigation process can help products achieve compliance.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia).
PharmaTech
NOVEMBER 5, 2023
To help improve adherence in children, drug developers need to consider innovative new dosage forms that can deliver flexible and convenient medications for young patients.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia).
Pharmaceutical Technology
NOVEMBER 5, 2023
BGB-16673 is under clinical development by BeiGene and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Pharmaceutical Technology
NOVEMBER 5, 2023
ALTO-100 is under clinical development by Alto Neuroscience and currently in Phase II for Post-Traumatic Stress Disorder (PTSD).
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmaceutical Technology
NOVEMBER 5, 2023
ALTO-100 is under clinical development by Alto Neuroscience and currently in Phase II for Post-Traumatic Stress Disorder (PTSD).
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.
Pharmaceutical Technology
NOVEMBER 5, 2023
Birociclib is under clinical development by Sihuan Pharmaceutical Holdings Group and currently in Phase I for Solid Tumor.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Myeloproliferative Disorders.
Pharmaceutical Technology
NOVEMBER 5, 2023
ALTO-300 is under clinical development by Alto Neuroscience and currently in Phase II for Major Depressive Disorder.
Pharmaceutical Technology
NOVEMBER 5, 2023
ABSK-021 is under clinical development by Abbisko Therapeutics and currently in Phase I for Small-Cell Lung Cancer.
Pharmaceutical Technology
NOVEMBER 5, 2023
(Favezelimab + pembrolizumab) is under clinical development by Merck and currently in Phase II for Bladder Cancer.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Myelodysplastic Syndrome.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
119 
Let's personalize your content